Evidence map›Paper›PMID 35845956›Full record

ArticleBioMed research international2022

Perilipin 2 Protects against Lipotoxicity-Induced Islet Fibrosis by Inducing Islet Stellate Cell Activation Phenotype Changes.

Yunting Zhou, Yuming Wang, Chengming Ni, Huiying Wang, Junming Zhou, Bingying Wan, Huiqin Li, Fengfei Li, Rong Huang, Wei Xu and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Yunting ZhouDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yuming WangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Chengming NiDepartment of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China.
Huiying WangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Junming ZhouDepartment of Cadre Gastroenterology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Bingying WanDepartment of Nephrology, Changzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Changzhou, China.
Huiqin LiDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Fengfei LiDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rong HuangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-0836-2845
Wei XuDepartment of Endocrinology, Xuzhou Central Hospital, Xuzhou Institute of Medical Sciences, Xuzhou Clinical School of Nanjing Medical University, Xuzhou, China.
Ting ShanDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Tingting CaiDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaoceng KongDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Bingli LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaomei LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zilin SunDepartment of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China.ORCID https://orcid.org/0000-0001-5357-5332
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-9383-2559
Nanjing Medical University · CNZhongda Hospital Southeast University · CNNanjing General Hospital of Nanjing Military Command · CNNanjing University of Chinese Medicine · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We explored whether and how perilipin 2 ( Methods: Six-week-old male rats were given a high-fat diet or a control diet for 28 weeks. Glucose metabolic phenotypes were assessed using glucose/insulin tolerance tests, masson, and immunohistochemical staining. ISCs activation levels were assessed from rats and palmitic acid- (PA-) treated cultured ISCs by immunofluorescence, Oil red O staining, electron microscopy, quantitative PCR, and western blotting. Changes in ISCs phenotype of activation degree and its underlying mechanisms were assessed by target gene lentiviral infection, high-performance liquid chromatography (HPLC), and western blotting. Results: Obese rats showed glucose intolerance, decreased endocrine hormone profiles, and elevated expression of Conclusions: Our observations suggest a protective role of

Indexed as

GlucosePancreatic Stellate CellsAnimalsFibrosisMalePerilipin-2PhenotypeRatsGlucosePerilipin-2

Identifiers

PMID35845956
PMCPMC9279040
OpenAlexW4285818007

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.